For Patients with Osteoarthritis Knee PainGo with a
Hyaluronic Acid
Designed for
Performance2,3*
Give them EUFLEXXA for improved function
and long-lasting
pain relief4†
Give them EUFLEXXA for improved function
and long-lasting
pain relief4†
*In a multicenter, prospective, randomized, controlled, double-blind, 12-week, pivotal clinical trial in patients with confirmed osteoarthritis (OA) of the knee (N=321), the primary
endpoint was noninferiority in safety and effectiveness between EUFLEXXA and Synvisc.2,3
†For up to 26 weeks in a controlled study assessing the safety and efficacy of EUFLEXXA vs saline.4
1. Rolling 12 month average of IQVIA claims data based on unique patients (November 2021). 2. EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 3. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162. 4. Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). Semin Arthritis Rheum. 2009;39(1):1-9.
EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].
EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
Do not inject intravascularly due to potential for systemic adverse events.
The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.
Please see FULL PRESCRIBING INFORMATION.